Cullen G. Taylor
Partner
Northern Virginia

Biography
Cullen Taylor helps life sciences companies structureand negotiate their most complex agreements,
particularly those involving the development,acquisition, and commercialization of intellectual
property and technology. Cullen takes a practical,
results-oriented approach to transactions, drawing on
his broad experience to anticipate and address
problems before they arise.

Phone

Cullen understands the legal and commercial risks thatarise as parties enter, live under, and exit long-term
partnering arrangements. Cullen is skilled at structuring
and drafting contracts that address these concerns
while keeping the client's business goals at front andcenter.

Languages

Cullen handles a variety of transactions within the life
sciences industry, including product acquisition,licensing, research and development, collaboration, copromotion, supply, and distribution agreements. Hisclients include pharmaceutical and biotechnology
companies and device and diagnostics manufacturers
with products and therapies at all stages ofdevelopment. Cullen is often called upon to advise suchclients on discovering, developing, and acquiring
cutting-edge therapies and innovative technologies.
Cullen is head of the firm's Life Sciences Licensing andCommercial Transactions team. He regularly
collaborates with his colleagues in the firm's Corporateand Regulatory practices to address intellectual
property and technology-related issues that arise in+1 703 610 6177

Fax
+1 703 610 6200

Emailcullen.taylor@hoganlovells.com

EnglishSpanishPractices
CommercialComplex ContractingIntellectual Property
IP and Technology Transactions

Industries
Life Sciences and Health Care
Technology and Telecoms

Areas of focus

corporate transactions and in the product approval
process, and has advised a number of clients onlicensing matters in relation to the recently
implemented Inflation Reduction Act.
Cullen was named Licensing and Collaboration
Attorney of the Year by IMG life Sciences in 2024, andhis team’s work on Daiichi Sankyo’s out-license ofthree DXD ADCs was awarded Impact Deal of the Yearby LMG Life Sciences in 2024.

IP Rights in Transactions
Technology Contracts
Medical Devices
Pharmaceuticals and Biotechnology
Cell, Tissue, and Gene Therapies
Licensing and Commercial
Transactions
Inflation Reduction Act

Representative experience
Representing Daiichi Sankyo in its out-license of threeDXD anti-body drug conjugates (named Impact Deal ofthe Year by LMG Life Sciences in 2024).

Education and admissions

Representing CereVasc on the China out-license of its
eShunt device to Lian Medical.

J.D., Harvard Law School, 2000
B.A., University of Virginia, withdistinction, Phi Beta Kappa, 1997

Representing Gilead Sciences in its collaboration with
Dragonfly Therapeutics to develop and commercialize
natural killer cell engagers in oncology andinflammation.

Education

Memberships

Representing Daiichi Sankyo in its collaboration with
AstraZeneca to develop and commercialize Daiichi
Sankyo's DS-1062, a potential treatment for multipletumor types.

Member, American Bar Association
Member, Virginia Bar Association

Representing Modex Therapeutics in its license andresearch collaboration with a multinational
pharmaceutical company for the development of MDX2201, Modex’s preclinical nanoparticle vaccine
candidate targeting Epstein-Barr virus.

Bar admissions andqualifications

Representing BMS on its in-license from Rockefeller
University of monoclonal antibodies for the treatmentof COVID-19
Representing Gilead Sciences and Kite Pharma in acollaboration and license arrangement with oNKoInnate to develop next-generation drug and engineered
cell therapies focused on natural killer cells.
Representing Gilead Sciences in its collaboration with
Yuhan Corporation to co-develop novel therapeutics
for patients with advanced fibrosis due to NASH.

VirginiaRepresenting Incyte Corporation in its license andcollaboration agreement with MacroGenics relating toan anti-PD-1 antibody.
Representing multiple pharmaceutical companies anddiagnostics manufacturers in collaboration agreements
to develop companion diagnostics for drug products.
Representing Regeneron in a genomics collaboration
with Geisinger Health Systems.
Representing Helsinn Healthcare in connection withlicense and collaboration agreements with MEI Pharma
and Taiho Pharmaceuticals.
Representing Cormedix in various license,
collaboration, supply, and distribution agreements
relating to its Neutrolin product.
Representing Daiichi Sankyo in its cocommercialization agreement with AstraZeneca
relating to MOVANTIK in the United States.
Representing Novartis in the sale of its animal healthbusiness to Eli Lilly for approximately US$5.4bn.

Awards and rankings
Licensing and Collaboration Attorney of the Year,LMG Life Sciences, 2024
IP Star - Transactions Star, Managing IP, 2023, 2024
Healthcare: Life Sciences, Recommended, Legal 500,2024Shortlisted for Licensing and Collaboration Attorneyof the Year, LMG Life Sciences, 2022
Ranked Practitioner, Licensing and Collaborations,
LMG Life Sciences, 2022
Practitioner of the Year (IP Transactions), Managing
IP, 2021
Media, Technology, and Telecoms: Technology
Transactions, Legal 500 US, 2019
BTI Client Service All-Star, BTI Consulting Group,
2017
Rising Star, Virginia Super Lawyers, 2008, 2010,

2015, 2019
Rising Star, Washington, D.C. Super Lawyers, 2015
Intellectual Property, Virginia Legal Elite, 2011
Young Lawyer, Virginia Legal Elite, 2010
Health Law, Virginia Legal Elite, 2009

Latest thinking and events
Hogan Lovells EventsTokyo: Life Sciences and Health Care Horizons
2024
NewsSpotlight on the U.S.: Panelists discuss navigating
the IRA
Press releases
Hogan Lovells advises Perspective Therapeutics ona series of strategic transactions with Lantheus anda US$69 million follow-on public offering of equity
securities
Hogan Lovells Events
Hogan Lovells APAC Life Sciences and Health Care
Webinar Series - Spotlight on the U.S. - Session 2
Press releases
Hogan Lovells advises Omega Therapeutics on
research collaboration transaction with Novo
Nordisk and Flagship Pioneering
Hogan Lovells Events
J.P. Morgan Healthcare Conference